{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:59:47Z","timestamp":1773763187010,"version":"3.50.1"},"reference-count":85,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFHZ0358"],"award-info":[{"award-number":["2024YFHZ0358"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Advanced liver fibrosis (LF) is a major determinant of prognosis across chronic liver diseases. Current biomarkers are often etiology-specific and lack cross-cohort robustness. Shared molecular drivers across etiologies remain incompletely defined, and effective anti-fibrotic therapies are limited. Methods: We developed a multi-algorithm consensus machine-learning framework to derive a robust LF progression signature. In the training non-alcoholic fatty liver disease (NAFLD) cohort GSE213621 (n = 368), samples were formulated as a binary classification task (mild fibrosis, F0\u2013F2; advanced fibrosis, F3\u2013F4). Candidate genes were screened in parallel using Boruta, Least Absolute Shrinkage and Selection Operator (LASSO), random forest, and eXtreme Gradient Boosting (XGBoost). Genes selected by at least two algorithms were defined as a high-consensus pool, and genes consistently selected by all four algorithms were prioritized to construct a core signature. Model performance was evaluated by stratified cross-validation in the training cohort and externally validated in four independent cohorts of different etiologies (GSE49541, GSE84044, GSE130970, and GSE276114). Cellular sources of signature genes were characterized using single-cell RNA sequencing (scRNA-seq) datasets GSE136103 (human) and GSE172492 (mouse). For therapeutic discovery, the high-consensus expression profile was queried against the Connectivity Map (CMap) to prioritize compounds predicted to reverse the fibrotic transcriptional program. Withaferin A (WFA) was selected for experimental validation in a carbon tetrachloride (CCl4)-induced mouse LF model and in the transforming growth factor-\u03b21 (TGF-\u03b21)-stimulated human hepatic stellate cell line LX-2. Bulk liver RNA-seq profiling was performed to interrogate WFA-associated molecular changes in vivo. Results: We identified a six-gene signature (CLEC4M, COL25A1, ITGBL1, NALCN, PAPPA, and PEG3) that discriminated advanced from mild fibrosis, achieving a mean AUC of 0.890 in internal cross-validation and an average AUC of 0.864 across external validation cohorts. scRNA-seq analysis revealed cell-type-specific expression with prominent enrichment in fibroblast populations. In vivo, WFA markedly attenuated CCl4-induced fibrosis (p &lt; 0.05) and reversed 1314 fibrosis-associated differentially expressed genes (adjusted p &lt; 0.05), which were enriched in fatty acid metabolism and PPAR signaling, as well as extracellular matrix (ECM)\u2013receptor interaction and focal adhesion (adjusted p &lt; 0.05). In vitro, WFA suppressed TGF-\u03b21-induced LX-2 activation, reducing \u03b1-SMA and Fibronectin expression (p &lt; 0.05). Conclusions: We report a six-gene signature that robustly predicts advanced LF across etiologies, define its cellular context using single-cell atlases, and validate the anti-fibrotic activity of WFA in both in vivo and in vitro models. Bulk liver RNA-seq and cellular evidence further suggest that WFA-associated effects are linked to lipid metabolic programs, ECM remodeling, and attenuation of hepatic stellate cell activation.<\/jats:p>","DOI":"10.3390\/ph19030495","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:03:27Z","timestamp":1773756207000},"page":"495","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From a Multi-Omics Signature to a Therapeutic Candidate: Computational Prediction and Experimental Validation in Liver Fibrosis"],"prefix":"10.3390","volume":"19","author":[{"given":"Yingying","family":"Qin","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"},{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuoshuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyuan","family":"Hong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Liang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Su","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine & State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-8041","authenticated-orcid":false,"given":"Yizhun","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"},{"name":"School of Pharmacy, Faculty of Medicine & State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolun","family":"Huang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China"},{"name":"School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macau SAR 999078, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014Aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1111\/liv.70001","article-title":"The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021","volume":"45","author":"Tham","year":"2025","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/CM9.0000000000003264","article-title":"Global epidemiology of liver cancer 2022: An emphasis on geographic disparities","volume":"137","author":"Li","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","article-title":"The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: A meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected Rapid Increase in the Burden of NAFLD in China from 2008 to 2018: A Systematic Review and Meta-Analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P.S., Caussy, C., Bettencourt, R., and Highlander, S.K. (2017). Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab., 25.","DOI":"10.1016\/j.cmet.2017.04.001"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"396","article-title":"Overall clinical and economic impact of non-alcoholic fatty liver disease","volume":"113","author":"Aller","year":"2021","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.cgh.2024.08.020","article-title":"Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis","volume":"23","author":"Zamani","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Castellanos","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_16","first-page":"1","article-title":"Regression of Liver Fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Roehlen, N., Crouchet, E., and Baumert, T.F. (2020). Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells, 9.","DOI":"10.3390\/cells9040875"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B.J., and Kaushal, K. (2022). Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis. Cells, 11.","DOI":"10.3390\/cells11091500"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jare.2025.06.019","article-title":"Multi-algorithm consensus classification identifies three distinct acute liver failure subtypes with differential treatment responses: A multi-database cohort study","volume":"82","author":"Yang","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, D., Zhang, Y., Liu, H., Chen, P., Zhao, Y., Sun, G., Zhao, W., and Dong, G. (2024). Multi-Algorithm-Integrated Tertiary Lymphoid Structure Gene Signature for Immune Landscape Characterization and Prognosis in Colorectal Cancer Patients. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112644"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"bbae659","DOI":"10.1093\/bib\/bbae659","article-title":"CDCM: A correlation-dependent connectivity map approach to rapidly screen drugs during outbreaks of infectious diseases","volume":"26","author":"Liao","year":"2024","journal-title":"Brief. Bioinform."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.121.000455","article-title":"Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights","volume":"50","author":"Xia","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lee, I.C., and Choi, B.Y. (2016). Withaferin-A\u2014A Natural Anticancer Agent with Pleitropic Mechanisms of Action. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030290"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhang, W., Ma, X., Tian, W., Teng, Y., and Ji, M. (2025). Cellular senescence defining the disease characteristics of Crohn\u2019s disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1616531"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","article-title":"Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease","volume":"185","author":"Choi","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Codotto, G., Blarasin, B., Tiribelli, C., Bellarosa, C., and Licastro, D. (2025). Decoding Liver Fibrosis: How Omics Technologies and Innovative Modeling Can Guide Precision Medicine. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062658"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100700","DOI":"10.1016\/j.medj.2025.100700","article-title":"DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population","volume":"6","author":"Liu","year":"2025","journal-title":"Med"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apt.16513","article-title":"PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease","volume":"54","author":"Madsen","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/liv.13536","article-title":"Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection","volume":"37","author":"Cao","year":"2017","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2741\/4403","article-title":"A 6 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis B","volume":"21","author":"Xu","year":"2016","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","article-title":"PNPLA3 Genotype and Diabetes Identify Patients with Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis","volume":"164","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Sun, J., You, Q., Lan, Z., and Zhu, Y. (2025). Letter to the Editor: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?. Hepatology.","DOI":"10.1097\/HEP.0000000000001481"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajhg.2014.11.006","article-title":"Recessive mutations in COL25A1 are a cause of congenital cranial dysinnervation disorder","volume":"96","author":"Shinwari","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-022-01356-1","article-title":"The amyloid plaque proteome in early onset Alzheimer\u2019s disease and Down syndrome","volume":"10","author":"Drummond","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neurobiolaging.2008.04.009","article-title":"Genetic association to the amyloid plaque associated protein gene COL25A1 in Alzheimer\u2019s disease","volume":"31","author":"Forsell","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jid.2024.06.1281","article-title":"Integrated Single-Cell Analysis Reveals Spatially and Temporally Dynamic Heterogeneity in Fibroblast States during Wound Healing","volume":"145","author":"Almet","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cochet-Bissuel, M., Lory, P., and Monteil, A. (2014). The sodium leak channel, NALCN, in health and disease. Front. Cell Neurosci., 8.","DOI":"10.3389\/fncel.2014.00132"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41586-020-2570-8","article-title":"Structure of the human sodium leak channel NALCN","volume":"587","author":"Kschonsak","year":"2020","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43446","DOI":"10.1038\/srep43446","article-title":"Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12985-025-02749-z","article-title":"HBV activates hepatic stellate cells through RUNX2\/ITGBL1 axis","volume":"22","author":"Shi","year":"2025","journal-title":"Virol. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/JHC.S306966","article-title":"Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection","volume":"8","author":"Ye","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"216244","DOI":"10.1016\/j.canlet.2023.216244","article-title":"Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer","volume":"566","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3892\/mmr.2020.11336","article-title":"CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma","volume":"22","author":"Yu","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_50","first-page":"1711","article-title":"High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma","volume":"19","author":"Luo","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"BSR20201648","DOI":"10.1042\/BSR20201648","article-title":"PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110662","DOI":"10.1016\/j.cellsig.2023.110662","article-title":"Epigenetic reactivation of PEG3 by EZH2 inhibitors suppresses renal clear cell carcinoma progress","volume":"107","author":"Qiu","year":"2023","journal-title":"Cell. Signal."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00280-024-04704-1","article-title":"Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression","volume":"94","author":"Xiang","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Wen, H., Peng, B., Weng, J., and Zeng, F. (2020). Downregulated microRNA-129-5p by Long Non-coding RNA NEAT1 Upregulates PEG3 Expression to Aggravate Non-alcoholic Steatohepatitis. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.563265"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10735-020-09949-7","article-title":"Elevated miR-129-5p attenuates hepatic fibrosis through the NF-\u03baB signaling pathway via PEG3 in a carbon CCl4 rat model","volume":"52","author":"Zhu","year":"2021","journal-title":"J. Mol. Histol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/endrev\/bnad017","article-title":"The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story","volume":"44","author":"Conover","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"eaay4145","DOI":"10.1126\/scitranslmed.aay4145","article-title":"PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans","volume":"12","author":"Ziegler","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bungau, S., Vesa, C.M., Abid, A., Behl, T., Tit, D.M., Purza, A.L., Pasca, B., Todan, L.M., and Endres, L. (2021). Withaferin A-A Promising Phytochemical Compound with Multiple Results in Dermatological Diseases. Molecules, 26.","DOI":"10.3390\/molecules26092407"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"113949","DOI":"10.1016\/j.fct.2023.113949","article-title":"Withaferin A: A potential selective glucocorticoid receptor modulator with anti-inflammatory effect","volume":"179","author":"Liang","year":"2023","journal-title":"Food Chem. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"155317","DOI":"10.1016\/j.phymed.2023.155317","article-title":"Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells","volume":"128","author":"Chen","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112807","DOI":"10.1016\/j.fct.2022.112807","article-title":"Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis","volume":"160","author":"Hamada","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2015.07.024","article-title":"Withaferin-A Reduces Acetaminophen-Induced Liver Injury in Mice","volume":"97","author":"Jadeja","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41419-020-03243-w","article-title":"Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3","volume":"12","author":"Xia","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/biof.1546","article-title":"Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2\/Snail1, vimentin, and NF\u03baB signaling","volume":"45","author":"Sayed","year":"2019","journal-title":"Biofactors"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: Archive for functional genomics data sets\u2014Update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e40214","DOI":"10.1097\/MD.0000000000040214","article-title":"Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine"},{"key":"ref_67","first-page":"290","article-title":"Histological scoring of chronic hepatitis","volume":"67","author":"Sempoux","year":"2004","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.eclinm.2024.102969","article-title":"Risk of intraoperative hemorrhage during cesarean scar ectopic pregnancy surgery: Development and validation of an interpretable machine learning prediction model","volume":"78","author":"Chen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11769343221123050","DOI":"10.1177\/11769343221123050","article-title":"Stability of scRNA-Seq Analysis Workflows is Susceptible to Preprocessing and is Mitigated by Regularized or Supervised Approaches","volume":"18","author":"Durmaz","year":"2022","journal-title":"Evol. Bioinform. Online"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/bioinformatics\/btaa751","article-title":"Systematic determination of the mitochondrial proportion in human and mice tissues for single-cell RNA-sequencing data quality control","volume":"37","author":"Osorio","year":"2021","journal-title":"Bioinformatics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"bbad142","DOI":"10.1093\/bib\/bbad142","article-title":"Decoding Connectivity Map-based drug repurposing for oncotherapy","volume":"24","author":"Zhao","year":"2023","journal-title":"Brief. Bioinform."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Stolfi, P., Manni, L., Soligo, M., Vergni, D., and Tieri, P. (2020). Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.545089"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s13073-014-0095-1","article-title":"Systematic evaluation of connectivity map for disease indications","volume":"6","author":"Cheng","year":"2014","journal-title":"Genome Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"The UniProt Consortium (2017). UniProt: The universal protein knowledgebase. Nucleic Acids Res., 45, D158\u2013D169.","DOI":"10.1093\/nar\/gkw1099"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"The UniProt Consortium (2023). UniProt: The Universal Protein Knowledgebase in 2023. Nucleic Acids Res., 51, D523\u2013D531.","DOI":"10.1093\/nar\/gkac1052"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118871","DOI":"10.1016\/j.jep.2024.118871","article-title":"Traditional uses, phytochemical constituents, pharmacological properties, and quality control of Pseudostellaria heterophylla (Miq.) Pax","volume":"337","author":"Lei","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.119.256792","article-title":"Withaferin A Improves Nonalcoholic Steatohepatitis in Mice","volume":"371","author":"Patel","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/bioinformatics\/btx373","article-title":"FQC Dashboard: Integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool","volume":"33","author":"Brown","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/or.2013.2487","article-title":"Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway","volume":"30","author":"Lee","year":"2013","journal-title":"Oncol. Rep."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/495\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:07:38Z","timestamp":1773756458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030495"],"URL":"https:\/\/doi.org\/10.3390\/ph19030495","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}